Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2022 Results Conference Call July 27, 2022 4:30 PM ET

Company Participants

Stephanie Diaz - Manager of Investor Relations

Brian Lian - President and Chief Executive Officer

Greg Zante - Chief Financial Officer

Conference Call Participants

Steven Seedhouse - Raymond James

Joseph Pantginis - H.C. Wainwright

Andy Hsieh - William Blair

Jay Olson - Oppenheimer

Yale Jen - Laidlaw & Company

Operator

Welcome to the Viking Therapeutics 2022 Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. Following management’s prepared remarks we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, July 27, 2022.

I would now like to turn the conference over to Viking’s Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Stephanie Diaz

Hello and thank you all for participating in today’s call. Joining me today is Brian Lian, Viking’s President and CEO; and Greg Zante, Viking’s CFO. Before we begin, I would like to caution that comments made during this conference call today, July 27, 2022, will contain Forward-Looking Statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking’s expectations regarding its development activities, time lines, and milestones.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today’s date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the Company’s filings with the Securities and Exchange Commission concerning these and other matters.

I will now turn the call over to Brian Lian for his initial comments.

Brian Lian

Thanks Stephanie. And thanks everyone dialed in by phone or listening on the webcast. Today, we will review our financial results for the second quarter of 2022 and provide an update on recent progress with our pipeline programs and operations.

During the second quarter, we continue to advance each of our three clinical programs. We respect to our lead compounds, VK2809, we continued enrollment in the Phase 2b VOYAGE study, targeting patients with biopsy confirmed NASH and fibrosis and we expect to complete enrollment in this study in the second half of the year.

We also continue to enroll subjects in a Phase I trial of our newest clinical program evaluating VK2735 a dual agonists of the glucagon like peptide-1 and glucose dependent insulinotropic polypeptide receptors.